Developing novel small RNA blood tests to improve human health

What drives us

Earlier, More Accurate Detection Saves Lives

We are pioneering the development of novel small RNA-based blood borne diagnostics for early disease detection of a broad range of indications.

Improving patient treatment

We have developed a best-in-class blood based complementary diagnostic for the selection of late-stage NSCLC patients most likely to benefit from immunotherapies with the goal of delivering immediate value and actionable clinical guidance.

Explore Hummingbird’s DiagnosticS pipeline for multiple diseases

Pipeline

Broad pipeline of proprietary, small RNA-based tests from blood.

miRisk

PREDICTION OF RESPONSE TO IMMUNOTHERAPY

•Blood-based small RNA panel that predicts immunotherapy response in stage IV NSCLC

•Significant and improved survival prediction (better than PD-L1 staining)

•Significant and immediate value for patients

miLung

EARLY DETECTION OF LUNG CANCER

•Blood-based small RNA panel that detects early-stage NSCLC

•Best performance reported from a blood test for early-stage lung cancer

Tackling unmet medical needs

Explore HumminGbird’s Pharma service options

PRODUCTS

Open to all kinds of partnering and collaboration projects involving small RNAs and Hummingbird’s highly sensitive, robust, and AI powered Next-Gen technology platform independent of the disease and application.

HBDx@clinic

miRCollect
Blood Collection Kit

For measurement of small RNA signatures from venous blood